Procyrion Stock

Procyrion, Inc., specializing in medical devices for cardiac and renal impairment, has successfully raised $57.7 million in Series E funding, led by Fannin Partners. This will fuel the DRAIN-HF trial for their Aortix device in treating acute decompensated heart failure (ADHF) patients, as well as support manufacturability improvements and commercialization efforts. Aortix aims to offer a groundbreaking solution for cardiorenal syndrome (CRS) patients, promising improved outcomes for this high-need group.

Procyrion™, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the completion of a $57.7 million Series E funding round, including the conversion of $10.0 million of interim financing. These funds will be used to support the ongoing DRAIN-HF pivotal IDE trial evaluating the Aortix™ percutaneous mechanical circulatory support (pMCS) device in patients with acute decompensated heart failure (ADHF) who remain congested despite standard medical therapy (cardiorenal syndrome or CRS).